{"date":"2025-04-26","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6838-2025-04-26-0906-8uky75","company_id":"6838","company":"台新藥","market":"上市","industry":"生技醫療","date":"2025-04-26","time":"09:06:55","subject":"公告本公司與Laboratorios Saval S.A.簽署眼部術後炎症和疼痛治療新藥APP13007於中南美洲市場之獨家授權合約","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台新藥（6838），2025-04-26 09:06，「公告本公司與Laboratorios Saval S.A.簽署眼部術後炎症和疼痛治療新藥APP13007於中南美洲市場之」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}